Clinical Trials Browser

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Completed

93 enrolled 16 charts

Breast

Estrogen Receptor-positive Breast Cancer

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast

Breast Neoplasms

NCT04796623 2026-04-08

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Phase 2 Completed

122 enrolled

Breast

HR-positive, HER2-negative Advanced Breast Cancer

NCT03643510 2026-03-16

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Phase 2 Completed

28 enrolled

Adenocarcinoma of Endometrium

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Phase 2 Completed

50 enrolled 14 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02860000 2026-02-27

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Phase 2 Completed

96 enrolled 34 charts

Breast

Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Phase 2 Completed

19 enrolled 10 charts

Breast

Breast Neoplasms

NCT03781063 2026-01-28

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Phase 2 Completed

100 enrolled

Breast

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05963984 2025-12-26

SUMIT-BC

Phase 2 Completed

60 enrolled

Breast

Breast Neoplasms

NCT02760030 2025-12-19

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

14 enrolled

Breast

Breast Neoplasms

NCT04603183 2025-12-12

ABIGAIL

Phase 2 Completed

162 enrolled

Breast

Breast Cancer Metastatic

NCT03620643 2025-10-30

ROLo

Phase 2 Completed

33 enrolled 13 charts

BreastGastrointestinal

Stomach Neoplasms, Carcinoma, Lobular, Triple Negative Breast Neoplasms

NCT02958852 2025-09-10

ABC-SE

Phase 2 Completed

126 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT04224272 2025-08-01

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Phase 2 Completed

51 enrolled 10 charts

Breast

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

Phase 2 Completed

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Phase 2 Completed

18 enrolled

Breast

Breast Neoplasms

NCT01441947 2025-05-25

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Phase 2 Completed

68 enrolled 11 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02206984 2025-03-11

Endocrine Response in Women With Invasive Lobular Breast Cancer

Phase 2 Completed

201 enrolled

Breast

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

Phase 2 Completed

36 enrolled 17 charts

Breast

Breast Neoplasms

NCT02491983 2024-12-09

PARSIFAL

Phase 2 Completed

486 enrolled 15 charts

Breast

Breast Neoplasms

NCT02632045 2024-12-06

MAINTAIN

Phase 2 Completed

169 enrolled 12 charts

Breast

Breast Neoplasms

NCT02216786 2024-12-02

MANTA

Phase 2 Completed

333 enrolled

Breast

Estrogen Receptor Positive Breast Cancer

NCT02675231 2024-11-26

monarcHER

Phase 2 Completed

237 enrolled 25 charts

Breast

Hormone Receptor Positive Breast Cancer

NCT03926936 2024-05-28

FUCHSia

Phase 2 Completed

17 enrolled

GynecologicSarcoma

Adenosarcoma of the uterus, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sex Cord-Gonadal Stromal Tumors

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

55 enrolled 15 charts

Breast

Breast Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT02536742 2024-02-26

PYTHIA

Phase 2 Completed

124 enrolled 10 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01142401 2023-11-27

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Phase 2 Completed

118 enrolled 11 charts

Breast

Breast Neoplasms

NCT03809988 2023-09-07

PALMIRA

Phase 2 Completed

198 enrolled

Breast

Breast Neoplasms

NCT03555877 2023-07-07

AMICA

Phase 2 Completed

56 enrolled

Breast

Breast Cancer Metastatic

NCT00921115 2023-05-19

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Phase 2 Completed

42 enrolled 5 charts

Breast

Breast Neoplasms

NCT02894398 2023-03-13

INGE-B

Phase 2 Completed

388 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Phase 2 Completed

118 enrolled 30 charts

Breast

Breast Neoplasms

NCT02756364 2023-02-08

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Phase 2 Completed

141 enrolled 18 charts

Breast

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

Phase 2 Completed

160 enrolled

Breast

Breast Neoplasms

NCT01670877 2022-04-15

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Phase 2 Completed

56 enrolled 29 charts

Breast

Breast Neoplasms

NCT02384239 2022-03-16

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

Phase 2 Completed

70 enrolled 16 charts

Breast

Breast Neoplasms

NCT00405938 2021-11-18

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

Phase 2 Completed

79 enrolled 7 charts

Breast

Breast Neoplasms

NCT00629616 2021-06-09

NIMFEA

Phase 2 Completed

116 enrolled

Breast

Breast Neoplasms

NCT02953860 2021-05-14

Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

Phase 2 Completed

32 enrolled 8 charts

Breast

Breast Neoplasms

NCT00871858 2021-02-24

HORGEN

Phase 2 Completed

120 enrolled 11 charts

Breast

Breast Neoplasms

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

379 enrolled

Thoracic

Lung Neoplasms

NCT00570323 2020-07-28

PACT001

Phase 2 Completed

72 enrolled 8 charts

Breast

Breast Neoplasms

NCT02530424 2020-07-15

NA-PHER2

Phase 2 Completed

102 enrolled

Breast

Breast Neoplasms

NCT02291913 2020-02-17

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Phase 2 Completed

48 enrolled 13 charts

Breast

Breast Neoplasms

NCT00313170 2020-01-06

FINDER II

Phase 2 Completed

144 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasms

NCT00451555 2019-11-01

Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

Phase 2 Completed

156 enrolled 15 charts

Breast

Breast Neoplasms

NCT00274469 2019-09-06

FIRST

Phase 2 Completed

205 enrolled 13 charts

Breast

Breast Neoplasms, Neoplasms

NCT02970682 2019-07-12

STEM

Phase 2 Completed

60 enrolled

Breast

Breast Neoplasms